New advances in the treatment of generalized lipodystrophy: role of metreleptin

about

Lipodystrophy syndromes Cardiac Manifestations of Congenital Generalized Lipodystrophy.

P2860

Q34597209-D9C2FFE7-0256-4F58-BDB4-D6D9C842BACF Q38808344-1A3E9F36-6799-48FE-885F-828EE51C742E

P2860

New advances in the treatment of generalized lipodystrophy: role of metreleptin

Item

http://www.wikidata.org/entity/Q26781946

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

New advances in the treatment of generalized lipodystrophy: role of metreleptin

@ast

New advances in the treatment of generalized lipodystrophy: role of metreleptin

@en

New advances in the treatment of generalized lipodystrophy: role of metreleptin

@nl

type

Item

label

New advances in the treatment of generalized lipodystrophy: role of metreleptin

@ast

New advances in the treatment of generalized lipodystrophy: role of metreleptin

@en

New advances in the treatment of generalized lipodystrophy: role of metreleptin

@nl

prefLabel

New advances in the treatment of generalized lipodystrophy: role of metreleptin

@ast

New advances in the treatment of generalized lipodystrophy: role of metreleptin

@en

New advances in the treatment of generalized lipodystrophy: role of metreleptin

@nl

P1476

New advances in the treatment of generalized lipodystrophy: role of metreleptin

@en

P2093

Gilberto J Paz-Filho

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical review#: Lipodystrophies: genetic and acquired body fat disorders

Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women.

Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy.

Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13.

AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34.

Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.

Metreleptin: first global approval.

Novel strategy for the use of leptin for obesity therapy

Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance.

Lipodystrophy: pathophysiology and advances in treatment

P304

1391-1400

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/TCRM.S66521

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Claudio A. Mastronardi

Alexander J Rodríguez

P577

2015-09-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281829302

http://www.w3.org/2001/XMLSchema#string

P698

26396524

http://www.w3.org/2001/XMLSchema#string

P932

4577254

http://www.w3.org/2001/XMLSchema#string

New advances in the treatment of generalized lipodystrophy: role of metreleptin

about

P2860

P2860

New advances in the treatment of generalized lipodystrophy: role of metreleptin

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P5875

P698

P932